Golvatinib clinical trials
Also written E7050.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses golvatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses golvatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and NeckCompletedPhase 1/2Eisai Inc.NCT01332266Written as E7050How we know
- A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)TerminatedPhase 1/2Eisai Inc.NCT01433991Written as GolvatinibHow we know
- A Study of E7050 Administered Orally to Patients With Advanced Solid TumorsCompletedPhase 1Eisai Co., Ltd.NCT00921869Written as E7050How we know
- E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric CancerTerminatedPhase 1/2Eisai Inc.NCT01355302Written as E7050How we know
- A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid TumorsCompletedPhase 1Eisai Inc.NCT00869895Written as E7050How we know
- Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy VolunteersCompletedPhase 1Eisai LimitedNCT02533102Written as E7050How we know
- A Phase I Study of E7050 in Subjects With Solid TumorsCompletedPhase 1Eisai Co., Ltd.NCT01428141Written as E7050How we know
Codes
What other systems call golvatinib · ClinicalTrials.gg INT005594
- UNII (FDA) 516Z3YP58EGOLVATINIBConfirmed FDA, Wikidata
- Wikidata Q27077829golvatinibConfirmed FDA, Wikidata
- NCI Thesaurus C82363GolvatinibOne source FDA
- DrugBank DB11977One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 516Z3YP58E | GOLVATINIB | Confirmed FDA, Wikidata |
| Wikidata | Q27077829 | golvatinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C82363 | Golvatinib | One source FDA |
| DrugBank | DB11977 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.